Search

Your search keyword '"Exenatide -- Reports"' showing total 47 results
Start Over Descriptor "Exenatide -- Reports"
47 results on '"Exenatide -- Reports"'

1. Researcher at Western Bank Has Published New Study Findings on Obesity (Treatment of hypothalamic obesity with GLP-1 analogs)

Subjects
Brain -- Reports, Medical research -- Reports, Medicine, Experimental -- Reports, Obesity -- Drug therapy, Banking industry -- Reports, Weight loss -- Drug therapy, Exenatide -- Reports, Banking industry, Health
Abstract

2024 DEC 7 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- A new study on obesity is now available. According to news reporting [...]

Published
2024

2. Study Findings from Yanbian University Hospital Provide New Insights into Glucose Elevating Agents (Dipeptidyl Peptidase-4 Disturbs Adipocyte Differentiation Via the Negative Regulation of the Glucagon-like Peptide-1/adiponectin-cathepsin K ...)

Subjects
Dextrose -- Reports, Cathepsins -- Reports, Glucose -- Reports, Physical fitness -- Reports, Glucagon -- Reports, Exenatide -- Reports, Health
Abstract

2024 JUN 22 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- A new study on Drugs and Therapies - Glucose Elevating Agents is [...]

Published
2024

3. GLP-1RAs Linked to Indirect Reductions in Blood Pressure

Author

Nye, Jessica

Subjects
Blood pressure -- Reports, Liraglutide -- Reports, Type 2 diabetes -- Reports, Exenatide -- Reports, Health
Abstract

The systolic blood pressure-lowering effects of glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment are likely due to reductions in weight, body mass index (BMI), and glycated hemoglobin (HbA[sub.1c]), according to study [...]

Published
2024

4. FORM 8-K: Vivani Medical, Inc. Files Current Report (Sep 26, 2024)

Subjects
United States. Securities and Exchange Commission -- Reports, Reports, Exenatide -- Reports, Financial statements -- Reports, Stock exchanges -- Reports, Securities law -- Reports, Stock-exchange -- Reports, Securities Exchange Act
Abstract

Washington: Vivani Medical, Inc., has filed FORM 8-K (Current Report) with the U.S. Securities and Exchange Commission on Sep 26, 2024: UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 [...]

Published
2024

5. FORM 8-K: Vivani Medical, Inc. Files Current Report (Sep 04, 2024)

Subjects
United States. Securities and Exchange Commission -- Reports, Reports, Exenatide -- Reports, Financial statements -- Reports, Stock exchanges -- Reports, Securities law -- Reports, Stock-exchange -- Reports, Securities Exchange Act
Abstract

Washington: Vivani Medical, Inc., has filed FORM 8-K (Current Report) with the U.S. Securities and Exchange Commission on Sep 04, 2024: UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 [...]

Published
2024

6. GLP Agonist Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working In The Therapeutics Segment

Subjects
Diabetes therapy -- Reports, Chronic diseases -- Reports, Clinical trials -- Reports, Type 2 diabetes -- Reports, Exenatide -- Reports, Pharmaceutical industry -- Reports, General interest, News, opinion and commentary
Abstract

New York: The GLP-1 receptor agonist market is experiencing significant growth due to the increasing prevalence of type 2 diabetes and obesity, and the high efficacy of these drugs in [...]

Published
2024

7. FORM 8-K: Vivani Medical, Inc. Files Current Report (Jun 13, 2024)

Subjects
United States. Securities and Exchange Commission -- Officials and employees, Securities law -- Reports, Stock-exchange -- Reports, Financial statements -- Reports, Type 2 diabetes -- Reports, Exenatide -- Reports, News, opinion and commentary, Securities Exchange Act
Abstract

Washington: Vivani Medical, Inc., has filed FORM 8-K (Current Report) with the U.S. Securities and Exchange Commission on Jun 13, 2024: UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 [...]

Published
2024

8. FORM 8-K: Vivani Medical, Inc. Files Current Report (Feb 28, 2024)

Subjects
United States. Securities and Exchange Commission -- Reports, Securities law -- Reports, Stock-exchange -- Reports, Financial statements -- Reports, Exenatide -- Reports, News, opinion and commentary, Securities Exchange Act
Abstract

Washington: Vivani Medical, Inc., has filed FORM 8-K (Current Report) with the U.S. Securities and Exchange Commission on Feb 28, 2024: UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 [...]

Published
2024

9. Half of Diabetes Patients Taking Class of Meds That Includes Ozempic, Mounjaro Stop Using Them

Subjects
Medical research -- Reports, Medicine, Experimental -- Reports, Diabetes therapy -- Reports, Liraglutide -- Reports, Type 2 diabetes -- Care and treatment, Exenatide -- Reports, Health, Ozempic (Medication) -- Reports, Mounjaro (Medication) -- Reports
Abstract

Byline: Ernie Mundell HealthDay Reporter TUESDAY, Dec. 12, 2023 (HealthDay News) -- Many Americans battling diabetes are turning to a new class of injected drugs that includes blockbusters like Ozempic [...]

Published
2023

10. Q1 2023 Invex Therapeutics Ltd Activities Report Call - Final

Subjects
United States. Food and Drug Administration -- Reports, Exenatide -- Reports, Business
Abstract

Presentation OPERATOR: Thank you for standing by, and welcome to the Invex Therapeutics Limited quarterly investor conference call. All participants are in a listen-only mode. There will be a presentation [...]

Published
2022

12. Global Extended Release Injectable Drugs Market Analysis Report 2023: Patient Compliance and Ease of Use, Healthcare Regulations, Managed Care Initiatives, Competitive Landscape, & Risk Factors

Subjects
Bupivacaine -- Reports, Lanreotide -- Reports, Patient compliance -- Reports, Managed care plans (Medical care) -- Reports, Vincristine -- Reports, Octreotide acetate -- Reports, Exenatide -- Reports, Company business management, Business, Business, international
Abstract

M2 PRESSWIRE-June 28, 2023-: Global Extended Release Injectable Drugs Market Analysis Report 2023: Patient Compliance and Ease of Use, Healthcare Regulations, Managed Care Initiatives, Competitive Landscape, & Risk Factors (C)1994-2023 [...]

Published
2023

13. Parkinson's Disease Clinical Trials and Therapies 2023: Latest breakthroughs, Treatment Market, Therapies, and Companies by DelveInsight | Abbvie, Roche, Kissei Pharmaceutical, Lundbeck, AstraZeneca

Subjects
AstraZeneca PLC -- Reports, Business -- Research, Rasagiline -- Reports, Pramipexole -- Reports, Pharmaceutical industry -- Reports, Exenatide -- Reports, Business, Business, international
Abstract

M2 PRESSWIRE-April 19, 2023-: Parkinson's Disease Clinical Trials and Therapies 2023: Latest breakthroughs, Treatment Market, Therapies, and Companies by DelveInsight | Abbvie, Roche, Kissei Pharmaceutical, Lundbeck, AstraZeneca (C)1994-2023 M2 COMMUNICATIONS [...]

Published
2023

14. Parkinson's Disease Drugs Pipeline 2023: Clinical Trials, Latest breakthroughs, Treatment Market, Therapies, and Companies by DelveInsight |Abbvie, Roche, Kissei Pharmaceutical, Lundbeck, AstraZeneca

Subjects
AstraZeneca PLC -- Reports, Business -- Research, Rasagiline -- Reports, Pramipexole -- Reports, Pharmaceutical industry -- Reports, Exenatide -- Reports, Business, Business, international
Abstract

M2 PRESSWIRE-April 10, 2023-: Parkinson's Disease Drugs Pipeline 2023: Clinical Trials, Latest breakthroughs, Treatment Market, Therapies, and Companies by DelveInsight |Abbvie, Roche, Kissei Pharmaceutical, Lundbeck, AstraZeneca (C)1994-2023 M2 COMMUNICATIONS RDATE:06042023 [...]

Published
2023

15. 140+ Active Companies working to Develop 150+ Pipeline Therapies for Parkinson's Disease Treatment

Subjects
Rasagiline -- Reports, Pramipexole -- Reports, Exenatide -- Reports, Business, Business, international
Abstract

M2 PRESSWIRE-March 24, 2023-: 140+ Active Companies working to Develop 150+ Pipeline Therapies for Parkinson's Disease Treatment (C)1994-2023 M2 COMMUNICATIONS RDATE:23032023 DelveInsight's, 'Parkinson's Disease Pipeline Insight 2023' report provides comprehensive [...]

Published
2023

16. DelveInsight Evaluates a Robust Alzheimer's Disease Pipeline as 150+ Influential Pharma Players to Set Foot in the Domain

Subjects
Eli Lilly and Co. -- Reports, Ionis Pharmaceuticals, Inc. -- Reports, Business -- Research, Medical research -- Reports, Medicine, Experimental -- Reports, Alzheimer's disease -- Reports, Industrial research -- Canada, Exenatide -- Reports, Research and development, General interest, News, opinion and commentary
Abstract

LAS VEGAS: DelveInsight Business Research, LLP has issued the following news release: The prevalence of Alzheimer's disease has been rising over the past few years, which prompts the growing demand [...]

Published
2023

17. Hypertension Clinical Trials and Pipeline Assessment Featuring 90+ Key Companies by DelveInsight

Subjects
United Therapeutics Corp. -- Reports, Boehringer Ingelheim GmbH -- Reports, Novartis AG -- Reports, Torrent Pharmaceuticals Ltd. -- Reports, Business -- Research, Cardiovascular agents -- Reports, Biotechnology industry -- Reports, Treprostinil -- Reports, Clinical trials -- Reports, Pharmaceutical industry -- Reports, Hypertension -- Reports, Exenatide -- Reports, Business, Business, international
Abstract

M2 PRESSWIRE-February 23, 2023-: Hypertension Clinical Trials and Pipeline Assessment Featuring 90+ Key Companies by DelveInsight (C)1994-2023 M2 COMMUNICATIONS RDATE:22022023 DelveInsight's 'Hypertension Pipeline Insight 2023' report provides comprehensive global coverage [...]

Published
2023

18. Parkinson's Disease Pipeline Insights and Clinical Trials 2023 | DelveInsight

Subjects
Business -- Research, Rasagiline -- Reports, Pramipexole -- Reports, Clinical trials -- Reports, Exenatide -- Reports, Business, Business, international
Abstract

M2 PRESSWIRE-January 16, 2023-: Parkinson's Disease Pipeline Insights and Clinical Trials 2023 | DelveInsight (C)1994-2023 M2 COMMUNICATIONS RDATE:13012023 DelveInsight's, 'Parkinson's Disease Pipeline Insight, 2023,' report provides comprehensive insights about 140+ [...]

Published
2023

19. Findings from Shiraz University of Medical Sciences in Alcoholic Fatty Liver Reported (The effects of glucagon-like peptide-1 receptor agonists on glycemic control and anthropometric profiles among diabetic patients with non-alcoholic fatty ...)

Subjects
Elsevier Science B.V. -- Reports, Diabetes therapy -- Reports, Fatty liver -- Care and treatment, Liver -- Reports, Type 2 diabetes -- Care and treatment, Diabetics -- Care and treatment, Liraglutide -- Reports, Periodical publishing -- Reports, Physical fitness -- Reports, Glucagon -- Reports, Exenatide -- Reports, Health
Abstract

2021 JAN 16 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Fresh data on Alcohol-Induced Diseases and Conditions - Alcoholic Fatty Liver are [...]

Published
2021

20. Studies from Guangzhou University of Chinese Medicine Describe New Findings in Antidiabetic Agents [Exenatide-loaded inside-porous poly(lactic-co-glycolic acid) microspheres as a long-acting drug delivery system with improved release ...]

Subjects
Drugs -- Vehicles, Diabetes therapy -- Reports, Medicine, Oriental -- Reports, Type 2 diabetes -- Reports, Drug delivery systems -- Reports, Physical fitness -- Reports, Exenatide -- Reports, Health
Abstract

2020 DEC 26 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- New research on antidiabetic agents is the subject of a new report. [...]

Published
2020

21. Researchers at Thomas Jefferson University Have Reported New Data on Antidiabetic Agents (Efficacy and Safety Over 2 Years of Exenatide Plus Dapagliflozin In the Duration-8 Study: a Multicenter, Double-blind, Phase 3, Randomized Controlled Trial)

Subjects
Clinical trials -- Reports, Exenatide -- Reports, Physical fitness -- Reports, Hemoglobins -- Reports, Type 2 diabetes -- Reports, Dapagliflozin -- Reports, Health, Thomas Jefferson University -- Reports
Abstract

2020 OCT 24 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators publish new report on Drugs and Therapies - Antidiabetic Agents. According [...]

Published
2020

23. Researchers at Novo Nordisk Discuss Findings in GLP-1 Receptor Agonist (A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK)

Subjects
Novo Nordisk A/S -- Reports, Exenatide -- Reports, Physical fitness -- Reports, Liraglutide -- Reports, Type 2 diabetes -- Reports, Biochemistry -- Reports, Body weight -- Reports, Pharmaceutical industry -- Reports, Glycosylated hemoglobin -- Reports, Dulaglutide -- Reports, Semaglutide -- Reports, Glucagon, Clinical trials, Obesity, Peptides, Hemoglobins, Editors, Hypoglycemic agents, Health
Abstract

2020 FEB 29 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Fresh data on Drugs and Therapies - GLP-1 Receptor Agonist are presented [...]

Published
2020

24. European Interbalkan Medical Center Researcher Provides New Data on Obesity and Diabetes (Effect of Glucagon-like Peptide-1 Receptor Agonists on Cardio-Metabolic Risk Factors among Obese/Overweight Individuals Treated with Antipsychotic Drug ...)

Subjects
Medical centers -- Reports, Obesity -- Drug therapy -- Risk factors, Diabetes therapy -- Reports, Mental health -- Reports, Antipsychotic drugs -- Reports, Liraglutide -- Reports, Type 2 diabetes -- Drug therapy -- Risk factors, Exenatide -- Reports, Glucagon -- Reports, Health, Psychology and mental health
Abstract

2023 MAR 13 (NewsRx) -- By a News Reporter-Staff News Editor at Mental Health Weekly Digest -- Research findings on obesity and diabetes are discussed in a new report. According [...]

Published
2023

25. Hypothalamic Obesity Market, Epidemiology, Pipeline, Companies, Drugs and Competitive Analysis by DelveInsight

Subjects
Brain -- Reports, Business -- Research, Obesity -- Reports, Epidemiology -- Reports, Exenatide -- Reports, Business, Business, international
Abstract

M2 PRESSWIRE-April 6, 2022-: Hypothalamic Obesity Market, Epidemiology, Pipeline, Companies, Drugs and Competitive Analysis by DelveInsight (C)1994-2022 M2 COMMUNICATIONS RDATE:05042022 (Albany, US) DelveInsight's 'Hypothalamic Obesity Market Insights, Epidemiology, and Market [...]

Published
2022

26. Investigators from China Pharmaceutical University Target Nanoparticles (Surface Decoration of Peptide Nanoparticles Enables Efficient Therapy Toward Osteoporosis and Diabetes)

Subjects
Osteoporosis -- Reports, Diabetes therapy -- Reports, Nanoparticles -- Reports, Nanotechnology -- Reports, Peptides -- Reports, Exenatide -- Reports, Biological sciences, Health
Abstract

2022 DEC 6 (NewsRx) -- By a News Reporter-Staff News Editor at Life Science Weekly -- Research findings on Nanotechnology - Nanoparticles are discussed in a new report. According to [...]

Published
2022

27. Parkinson's Disease Pipeline Offers Promising New Options for Treatment | DelveInsight

Subjects
Rasagiline -- Reports, Pramipexole -- Reports, Exenatide -- Reports, Banking, finance and accounting industries, Business
Abstract

Los Angeles, USA, Jan 17, 2022 (GLOBE NEWSWIRE via COMTEX) -- Parkinson's Disease Pipeline Offers Promising New Options for Treatment | DelveInsight DelveInsight's 'Parkinson's Disease Pipeline Insight' report provides comprehensive [...]

Published
2022

28. Researchers at Bharti Hospital Report New Data on Antidiabetic Agents (Exenatide Implant Therapy In Diabetes)

Subjects
Exenatide -- Reports, Drug delivery systems -- Reports, Physical fitness -- Reports, Type 2 diabetes -- Reports, Diabetes therapy -- Reports, Glucagon, Obesity, Prostheses and implants, Peptides, Editors, Hypoglycemic agents, Health
Abstract

2019 JUN 1 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Fresh data on Drugs and Therapies - Antidiabetic Agents are presented in [...]

Published
2019

29. Studies in the Area of Alzheimer Disease Reported from A. Robinson and Co-Researchers (Combination of Insulin With a Glp1 Agonist Is Associated With Better Memory and Normal Expression of Insulin Receptor Pathway Genes In a Mouse Model of ...)

Subjects
Exenatide -- Reports, Physical fitness -- Reports, House mouse -- Reports, Medical research -- Reports, Genes -- Reports, Alzheimer's disease -- Reports, Insulin -- Reports, Obesity, Liquor, Hypoglycemic agents, Neurodegenerative diseases, Advertising executives, Anopheles, Editors, Health
Abstract

2019 MAY 18 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Research findings on Neurodegenerative Diseases and Conditions - Alzheimer Disease are discussed [...]

Published
2019

30. Analysis of the The FDA Amendments Act (FDAAA)

Subjects
Drug approval -- Reports, Lamotrigine -- Reports, Exenatide -- Reports, Banking, finance and accounting industries, Business, Food and Drug Administration Amendments Act of 2007
Abstract

Dublin, July 21, Jul 21, 2021 (GLOBE NEWSWIRE via COMTEX) -- The 'Trends: Hot Topic Catalyst' report has been added to ResearchAndMarkets.com's offering. Receipt of a CRL slows approval, causing [...]

Published
2021

31. Alzheimer's Disease (AD) Pipeline Insight Report 2020: Comprehensive Insights for Approx 100+ Companies and 100+ Pipeline Drugs

Subjects
Advertising executives -- Reports, Alzheimer's disease -- Reports, Exenatide -- Reports, General interest, News, opinion and commentary
Abstract

DUBLIN: Research and Markets has issued the following news release: The 'Alzheimer's Disease (AD) - Pipeline Insight, 2020' drug pipelines has been added to ResearchAndMarkets.com's offering. This 'Alzheimer's Disease (AD) [...]

Published
2021

32. Alzheimer's Disease (AD) Pipeline Insight Report 2020: Comprehensive Insights for Approx 100+ Companies and 100+ Pipeline Drugs - ResearchAndMarkets.com

Subjects
Advertising executives -- Reports, Alzheimer's disease -- Reports, Exenatide -- Reports, Business, Business, international
Abstract

DUBLIN -- The 'Alzheimer's Disease (AD) - Pipeline Insight, 2020' drug pipelines has been added to ResearchAndMarkets.com's offering. This 'Alzheimer's Disease (AD) - Pipeline Insight, 2020,' report provides comprehensive insights [...]

Published
2021

33. Alzheimer's Disease (AD) Pipeline Insight Report 2020: Comprehensive Insights for Approx 100+ Companies and 100+ Pipeline Drugs

Subjects
Advertising executives -- Reports, Alzheimer's disease -- Reports, Exenatide -- Reports, Business, Business, international
Abstract

M2 PRESSWIRE-January 5, 2021-: Alzheimer's Disease (AD) Pipeline Insight Report 2020: Comprehensive Insights for Approx 100+ Companies and 100+ Pipeline Drugs (C)1994-2021 M2 COMMUNICATIONS RDATE:05012021 The 'Alzheimer's Disease (AD) - [...]

Published
2021

34. Hypothalamic Obesity Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight

Subjects
Brain -- Reports, Business research -- Reports, Exenatide -- Reports, Obesity -- Reports, Epidemiology -- Reports, Business, Business, international
Abstract

M2 PRESSWIRE-December 11, 2020-: Hypothalamic Obesity Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight (C)1994-2020 M2 COMMUNICATIONS RDATE:11122020 (Albany, US) DelveInsight has launched a new report on [...]

Published
2020

35. Researchers from Van Andel Institute Report Recent Findings in Parkinson's Disease (An Extended Release Glp-1 Analogue Increases Alpha-synuclein Accumulation In a Mouse Model of Prodromal Parkinson's Disease)

Subjects
Medical research -- Reports, Medicine, Experimental -- Reports, Diabetes therapy -- Reports, Type 2 diabetes -- Reports, Exenatide -- Reports, Health
Abstract

2021 JUL 23 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Current study results on Neurodegenerative Diseases and Conditions - Parkinson's Disease have been [...]

Published
2021

36. Study Findings on Type 2 Diabetes Reported by Researchers at Section of Endocrinology (GLP-1 receptor agonists for NAFLD treatment in patients with and without type 2 diabetes: an updated meta-analysis)

Subjects
Biochemistry -- Reports, Diabetes therapy -- Reports, Type 2 diabetes -- Care and treatment, Liraglutide -- Reports, Exenatide -- Reports, Health
Abstract

2021 JUL 16 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- New research on type 2 diabetes is the subject of a new report. [...]

Published
2021

37. Researchers' Work from University of Michigan Focuses on Biopharmaceuticals (Characterization of Attributes and In Vitro Performance of Exenatide-loaded Plga Long-acting Release Microspheres)

Subjects
Biopharmaceutics -- Reports, Diabetes therapy -- Reports, Pharmaceutical biotechnology -- Reports, Type 2 diabetes -- Reports, Exenatide -- Reports, Biotechnology industry, Pharmaceuticals and cosmetics industries, University of Michigan -- Reports
Abstract

2021 MAR 31 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- Investigators publish new report on Biotechnology - Biopharmaceuticals. According to news originating from Ann Arbor, [...]

Published
2021

38. Outlook on the Sustained Release Injectables Market to 2026 - Featuring Eli Lilly, AstraZeneca, Ipsen, Novartis, Roche, Sanofi, and More

Subjects
Novartis AG -- Forecasts and trends -- Reports, AstraZeneca PLC -- Forecasts and trends -- Reports, Eli Lilly and Co. -- Forecasts and trends -- Reports, Sanofi S.A. -- Forecasts and trends -- Reports, Aripiprazole -- Reports, Drugs -- Vehicles, Bupivacaine -- Reports, Lanreotide -- Reports, Vincristine -- Reports, Marketing -- Reports, Drug delivery systems -- Reports, Pharmaceutical industry -- Forecasts and trends -- Reports, Somatropin -- Reports, Exenatide -- Reports, Market trend/market analysis, Business, News, opinion and commentary
Abstract

DUBLIN, Sept. 24, 2019 /PRNewswire/ -- The 'Sustained Release Injectables to 2026' report has been added to ResearchAndMarkets.com's offering. Sustained Release Injectables to 2026 is a comprehensive evaluation and analysis [...]

Published
2019

39. Sustained Release Injectables Markets, 2026 - ResearchAndMarkets.com

Subjects
Exenatide -- Reports, Drug delivery systems -- Reports, Bupivacaine -- Reports, Somatropin -- Reports, Vincristine -- Reports, Aripiprazole -- Reports, Marketing -- Reports, Pharmaceutical industry -- Forecasts and trends -- Reports, Lanreotide -- Reports, Paliperidone -- Reports, Business logistics, Technology, Market trend/market analysis, Business, Business, international
Abstract

DUBLIN -- The 'Sustained Release Injectables to 2026' report has been added to ResearchAndMarkets.com's offering. Sustained Release Injectables to 2026 is a comprehensive evaluation and analysis of the technology, products [...]

Published
2019

40. Sustained Release Injectables Markets, 2026

Subjects
Exenatide -- Reports, Drug delivery systems -- Reports, Bupivacaine -- Reports, Somatropin -- Reports, Vincristine -- Reports, Aripiprazole -- Reports, Marketing -- Reports, Pharmaceutical industry -- Forecasts and trends -- Reports, Lanreotide -- Reports, Paliperidone -- Reports, Business logistics, Technology, Market trend/market analysis, Business, Business, international
Abstract

M2 PRESSWIRE-August 12, 2019-: Sustained Release Injectables Markets, 2026 (C)1994-2019 M2 COMMUNICATIONS RDATE:12082019 The 'Sustained Release Injectables to 2026' report has been added to ResearchAndMarkets.com's offering. Sustained Release Injectables to [...]

Published
2019

41. Peptides and Heparin Market Scenario Highlighting Major Drivers & Trends through 2017-2026

Subjects
Peptides -- Reports, Motor vehicle drivers -- Reports, Heparin -- Reports, Exenatide -- Reports, Liraglutide -- Reports, Anticoagulants, Technology, General interest
Abstract

New Delhi, March 26 -- This research report titled 'Peptides and Heparin Market Scenario Highlighting Major Drivers & Trends through 2017-2026' focuses on the peptides and heparin market, published to [...]

Published
2019

42. EXOSOMES HELP TRACK EFFECTIVENESS OF EXPERIMENTAL PARKINSON'S DISEASE DRUG

Subjects
United States. National Institute on Aging -- Reports, Exenatide -- Reports, Antiparkinson agents -- Reports, Neurons, Brain research, News, opinion and commentary
Abstract

BETHESDA, MD -- The following information was released by the National Institute on Aging (NIA): Exosomesnanoscale particles that are produced by all types of cells and circulate in the bloodstreamhave [...]

Published
2019

43. Peptides and Heparin Market Development and Trends Report through 2017-2026

Subjects
Peptides -- Reports, Heparin -- Reports, Exenatide -- Reports, Liraglutide -- Reports, Anticoagulants, Technology, General interest
Abstract

India, March 18 -- This research report titled 'Peptides and Heparin Market Development and Trends Report through 2017-2026' focuses on the peptides and heparin market, published to the vast repository [...]

Published
2019

44. Researchers at Laboratory of Clinical Pharmacology and Therapeutics Discuss Findings in Parkinson's Disease (GLP-1 receptor agonists for Parkinson's disease)

Subjects
Exenatide -- Reports, Pharmacology -- Reports, Type 2 diabetes -- Drug therapy, Diabetes therapy -- Reports, Medical research -- Reports, Health
Abstract

2020 AUG 7 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Investigators publish new report on Neurodegenerative Diseases and Conditions - Parkinson's Disease. According [...]

Published
2020

45. Researchers from University College London (UCL) Institute of Neurology Provide Details of New Studies and Findings in the Area of Parkinson's Disease (Repurposing anti-diabetic drugs for the treatment of Parkinson's disease: Rationale and ...)

Subjects
Exenatide -- Reports, Dementia, Neurodegenerative diseases, L-dopa, Type 2 diabetes, Editors, Hypoglycemic agents, Diseases, Health
Abstract

2020 APR 24 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Investigators publish new report on Neurodegenerative Diseases and Conditions - Parkinson's Disease. According [...]

Published
2020

46. Researchers from China Pharmaceutical University Detail New Studies and Findings in the Area of Antidiabetic Agents (Novel glucagon- and OXM-based peptides acting through glucagon and GLP-1 receptors with body weight reduction and anti-diabetic ...)

Subjects
Exenatide -- Reports, Obesity -- Reports, Glucagon -- Reports, Diabetes therapy -- Reports, Body weight -- Reports, Weight loss -- Reports, Hormones, Peptides, Finance, Editors, Hypoglycemic agents, Health
Abstract

2020 FEB 10 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity & Diabetes Week -- Investigators publish new report on Drugs and Therapies - Antidiabetic Agents. According to [...]

Published
2020

47. Study Results from Medical University of Silesia Broaden Understanding of Antidiabetic Agents (Exenatide Modulates Expression of Metalloproteinases and Their Tissue Inhibitors In Tnf-alpha Stimulated Human Retinal Pigment Epithelial Cells)

Subjects
Exenatide -- Reports, Tumor necrosis factor -- Reports, Diabetics -- Reports, Homeostasis, Hyperglycemia, Blindness, Editors, Health
Abstract

2019 MAR 18 (NewsRx) -- By a News Reporter-Staff News Editor at Diabetes Week -- Investigators publish new report on Drugs and Therapies - Antidiabetic Agents. According to news reporting [...]

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results